AGA Medical Wraps Up Septal Occluder Trial Enrollment For ASD Repair
This article was originally published in The Gray Sheet
Executive SummaryAGA Medical plans to submit initial data in early 1999 supporting a premarket approval application for its Amplatzer septal occluder for treatment of atrial septal defects. Over the next two to three months, the company expects to complete the control arm of the pivotal study, a prospective surgical cohort.
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.
The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.